Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
admin Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreBanking
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreChina’s offshore yuan falls to record low against U.S. dollar
China’s currency hit its weakest ever offshore trading level against the U.S. dollar, with the…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read MoreBig banks to pay nearly $2 billion for ‘widespread and longstanding failures’ in keeping text-message records
Nearly a dozen financial institutions agreed to pay more than $1.8 billion collectively for failing…
Read MoreBank of America clients are buying the dip in U.S. stocks, shifting from cyclicals to defensive
In light of the recent U.S. stock market losses, Bank of America (BofA) saw more…
Read More‘The motivation was greed’: Ex-Nigerian official gets 5 years for stealing US disaster funds
A former government official in Nigeria has been sentenced to five years in a U.S.…
Read MoreWatchdog blasts top House Democrats’ plan for banning congressional stock trading: ‘They’ve included poison pills’
Top House Democrats have offered a proposal for stopping congressional stock trading, but it’s drawing…
Read MoreMedicare premiums are decreasing in 2023 – this is how much older Americans will save if they’re on Part B
Medicare beneficiaries will see their Part B premiums go down for the first time in…
Read MoreA GOP takeover of the House could be a boon for crypto legislation
With polls indicating Republicans will take control of at least the House of Representatives after…
Read More